Edgewise Therapeutics (EWTX) Common Equity (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Common Equity data on file, last reported at $493.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 14.77% year-over-year to $493.2 million; the trailing twelve-month figure through Mar 2026 stood at $493.2 million (up 14.77% YoY), and the FY2025 full-year result was $522.3 million, up 13.73% from the prior year.
• Common Equity eased to $493.2 million in Q1 2026, from $522.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $589.1 million in Q2 2025 to a low of $246.4 million in Q2 2022.
• A 5-year average of $414.8 million and a median of $429.7 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 68.33% in 2024 and decreased 19.67% in 2025, its largest moves.
• Tracing EWTX's Common Equity over 5 years: stood at $346.7 million in 2022, then slipped by 8.04% to $318.8 million in 2023, then surged by 44.03% to $459.2 million in 2024, then rose by 13.73% to $522.3 million in 2025, then decreased by 5.56% to $493.2 million in 2026.
• Business Quant data shows EWTX's Common Equity at $493.2 million in Q1 2026, $522.3 million in Q4 2025, and $558.6 million in Q3 2025.